NCT05280314Phase 2Recruiting

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Study sponsor: IO Biotech

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-04-30Estimated

Enrollment · participants60Estimated

Source updated2024-03-18Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Melanoma; Squamous Cell Carcinoma of Head and Neck

Treatments or interventions studied

IO102-IO103Drug
Pembrolizumab KEYTRUDA®Drug

Primary outcomes · main study measures

measure: Major pathologic response; description: Major pathologic response, defined as pathologic complete response (pCR) (0% residual viable tumor) or near pCR (≤10% residual viable tumor); timeFrame: Observed in the resected tumor tissue after neoadjuvant treatment at surgery

History coverage

Imported research includes version dates later than the current official API record (2024-03-18). Disputed observations are retained for audit and excluded from trusted change feeds and sponsor statistics. Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history